The study successfully met its primary safety endpoint and demonstrated a 76-77% slower cognitive decline from baseline in the active treatment group compared to the sham group that was nominally significant ( 156 ).
← all excerpts
Modifying Alzheimer's disease pathophysiology with photobiomodulation: model, evidence, and future with EEG-guided intervention.
1
—
—